Charles River Laboratories Announces First-Quarter 2016 Results from Continuing Operations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500, Dow set to open lower as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- Citi initiates UiPath coverage with Buy rating and $23 target
- Trump says Canada's Bombardier must build jets in US or lose market access
- European shares subdued as surging crude sharpens focus on ECB rate path
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Alibaba (BABA) PT Lowered to $165 at Bernstein SocGen Group
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Charles River Laboratories (CRL) PT Increases to $83 - UBS
May 5, 2016 9:00 AM EDTUBS analyst, Jonathan Groberg, raised his PT on Charles River Labs (NYSE: CRL) to $83 from $76 but maintained his Neutral rating after 1Q16 beats and management raises full year EPS guidance. Revenue of $355m was in-line with consensus estimates and EPS of $0.98 was above consensus estimates... More
Charles River Laboratories (CRL) Tops Q1 EPS by 8c; Boosts FY16 EPS Outlook
May 4, 2016 7:33 AM EDTCharles River Laboratories (NYSE: CRL) reported Q1 EPS of $0.98, $0.08 better than the analyst estimate of $0.90. Revenue for the quarter came in at $354.9 million versus the consensus estimate of $354.91 million.
GUIDANCE:
Charles River Laboratories sees FY2016 EPS of $4.32-$4.45, versus the... More
